• +1-646-491-9876
    • +91-20-67278686

    Search

    Peritonitis - Pipeline Review, H2 2016

    Peritonitis - Pipeline Review, H2 2016

    • Report Code ID: RW0001492629
    • Category Pharmaceuticals
    • No. of Pages 48
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Peritonitis - Pipeline Review, H2 2016, provides an overview of the Peritonitis (Gastrointestinal) pipeline landscape.

    Peritonitis is inflammation of the peritoneum. There are two types of peritonitis. Spontaneous bacterial peritonitis (SBP) is the result of an infection of the fluid in peritoneal cavity. Secondary peritonitis is usually due to an infection that has spread from digestive tract. Symptoms include abdominal bloating, nausea and vomiting, diarrhea, fatigue, fever and chills. Treatment includes antibiotics.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Peritonitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peritonitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Peritonitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peritonitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Peritonitis.

    Peritonitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Peritonitis (Gastrointestinal).
    - The pipeline guide reviews pipeline therapeutics for Peritonitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Peritonitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Peritonitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Peritonitis (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Peritonitis (Gastrointestinal).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Peritonitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Peritonitis Overview 6
    Therapeutics Development 7
    Pipeline Products for Peritonitis - Overview 7
    Pipeline Products for Peritonitis - Comparative Analysis 8
    Peritonitis - Therapeutics under Development by Companies 9
    Peritonitis - Therapeutics under Investigation by Universities/Institutes 10
    Peritonitis - Pipeline Products Glance 11
    Clinical Stage Products 11
    Early Stage Products 12
    Peritonitis - Products under Development by Companies 13
    Peritonitis - Products under Investigation by Universities/Institutes 14
    Peritonitis - Companies Involved in Therapeutics Development 15
    Adenium Biotech ApS 15
    Allergan Plc 16
    GlaxoSmithKline Plc 17
    Oncodesign SA 18
    Peritonitis - Therapeutics Assessment 19
    Assessment by Monotherapy Products 19
    Assessment by Target 20
    Assessment by Mechanism of Action 22
    Assessment by Route of Administration 24
    Assessment by Molecule Type 26
    Drug Profiles 28
    AA-139 - Drug Profile 28
    Product Description 28
    Mechanism Of Action 28
    R&D Progress 28
    AcPepA - Drug Profile 29
    Product Description 29
    Mechanism Of Action 29
    R&D Progress 29
    cenicriviroc mesylate - Drug Profile 30
    Product Description 30
    Mechanism Of Action 30
    R&D Progress 30
    ECL-1 - Drug Profile 37
    Product Description 37
    Mechanism Of Action 37
    R&D Progress 37
    molgramostim - Drug Profile 38
    Product Description 38
    Mechanism Of Action 38
    R&D Progress 38
    R-10001 - Drug Profile 39
    Product Description 39
    Mechanism Of Action 39
    R&D Progress 39
    Small Molecules to Inhibit Nitric Oxide Synthase for Rheumatism, Arthritis and Peritonitis - Drug Profile 40
    Product Description 40
    Mechanism Of Action 40
    R&D Progress 40
    Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile 41
    Product Description 41
    Mechanism Of Action 41
    R&D Progress 41
    SRT-3025 - Drug Profile 42
    Product Description 42
    Mechanism Of Action 42
    R&D Progress 42
    Stem Cell Therapy for Inflammation, Corneal Injury and Peritonitis - Drug Profile 44
    Product Description 44
    Mechanism Of Action 44
    R&D Progress 44
    Peritonitis - Dormant Projects 45
    Peritonitis - Product Development Milestones 46
    Featured News & Press Releases 46
    Mar 20, 2015: Tobira Therapeutics Highlights Presentations at the AASLD's Industry Colloquium for Novel Targets and Therapies in Liver Disease 46
    Appendix 47
    Methodology 47
    Coverage 47
    Secondary Research 47
    Primary Research 47
    Expert Panel Validation 47
    Contact Us 47
    Disclaimer 48

    List of Tables

    Number of Products under Development for Peritonitis, H2 2016 7
    Number of Products under Development for Peritonitis - Comparative Analysis, H2 2016 8
    Number of Products under Development by Companies, H2 2016 9
    Number of Products under Investigation by Universities/Institutes, H2 2016 10
    Comparative Analysis by Clinical Stage Development, H2 2016 11
    Comparative Analysis by Early Stage Development, H2 2016 12
    Products under Development by Companies, H2 2016 13
    Products under Investigation by Universities/Institutes, H2 2016 14
    Peritonitis - Pipeline by Adenium Biotech ApS, H2 2016 15
    Peritonitis - Pipeline by Allergan Plc, H2 2016 16
    Peritonitis - Pipeline by GlaxoSmithKline Plc, H2 2016 17
    Peritonitis - Pipeline by Oncodesign SA, H2 2016 18
    Assessment by Monotherapy Products, H2 2016 19
    Number of Products by Stage and Target, H2 2016 21
    Number of Products by Stage and Mechanism of Action, H2 2016 23
    Number of Products by Stage and Route of Administration, H2 2016 25
    Number of Products by Stage and Molecule Type, H2 2016 27
    Peritonitis - Dormant Projects, H2 2016 45

    List of Figures

    Number of Products under Development for Peritonitis, H2 2016 7
    Number of Products under Development for Peritonitis - Comparative Analysis, H2 2016 8
    Number of Products under Development by Companies, H2 2016 9
    Comparative Analysis by Clinical Stage Development, H2 2016 11
    Comparative Analysis by Early Stage Products, H2 2016 12
    Assessment by Monotherapy Products, H2 2016 19
    Number of Products by Targets, H2 2016 20
    Number of Products by Stage and Targets, H2 2016 20
    Number of Products by Mechanism of Actions, H2 2016 22
    Number of Products by Stage and Mechanism of Actions, H2 2016 22
    Number of Products by Routes of Administration, H2 2016 24
    Number of Products by Stage and Routes of Administration, H2 2016 24
    Number of Products by Molecule Types, H2 2016 26
    Number of Products by Stage and Molecule Types, H2 2016 26
    Adenium Biotech ApS
    Allergan Plc
    GlaxoSmithKline Plc
    Oncodesign SA

    Request for Sample

    Report Url https://www.reportsweb.com//peritonitis-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//peritonitis-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//peritonitis-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments